DEVELOPMENT AND VALIDATION OF HPLC METHOD FOR QUANTIFICATION OF CEFOTAXIME IN PLASMA OF PATANWADI SHEEP

Present research work was carried out to study the validation procedure of Cefotaxime using plasma of Patanwadi sheep. The samples were analyzed using RP- HPLC C18 column (250 X 4.6 mm) with UV detection (254 nm). The method was developed for extraction of Cefotaxime from plasma of sheep using acetonitrile and was validated. The mobile phase was a mixture of 0.05 M potassium dihydrogen phosphate buffer with pH 6 and acetonitrile (88: 12, v/v). The method was validated with respect to linearity, precision and accuracy. The intra day and inter day precision study of cefotaxime was carried out by estimating the corresponding responses 3 times on the same day and on 3 different days (1st, 2nd and 3rd ) for 6 different concentration of Cefotaxime (10, 5, 2.5, 0.625, 0.312 and 0.156 µg/ml) and the results were reported in terms of relative standard deviation (RSD). At all concentration studied the C.V. (Coefficient of Variance) was less than 7%. The recovery of Cefotaxime from plasma varied from 85-89%. The limit of detection (LOD) was found to be 0.156 ppm. Calibration graphs showed a linear correlation (r > 0.998) over the concentration ranges of 1.56 – 200 µg mL-1 for plasma. The results obtained indicated good precision of assay. The developed method was found to be simple, sensitive, accurate, precise and reproducible and can be used for analytical studies of Cefotaxime

Safety of Moxifloxacin following repeated intramuscular administration in Wistar rats

Moxifloxacin is a novel fourth generation fluoroquinolone with broad spectrum of antibacterial activity. The study was conducted to evaluate the safety of Moxifloxacin (5.0 mg/kg) after repeated intramuscular administration at 24 h interval for 14 days in male and female wistar rats. Hematological (Haemoglobin, RBC, WBC, MCV, MCH, MCHC, HCT and DLC), blood biochemical parameters (AST, ALT, ALP, Total Bilirubin, Total Serum Protein, Serum Albumin, Globulin, Serum Creatinine, Urea, Uric acid and Blood glucose) and histopathological examination of various tissues were carried out in the present study. Male and female animals of any group did not reveal any clinical symptoms and mortality attributable to the 14 days intramuscular administration of Moxifloxacin. The data were compared by unpaired two tail `t` test using Graph Pad Prism (Version 4.00). All above hematological and blood biochemical parameters were found to fluctuate within normal range during treatment period and the mean values were not significantly differ (p < 0.05) from corresponding control values. Moreover, no gross or microscopic changes were found in the liver, kidney, heart, spleen, stomach, intestine and joint cartilages of the treated wistar rats. Results indicate that daily administration of Moxifloxacin for 14 days seems to be safe and well tolerated in rats. [Veterinary World 2010; 3(10.000): 449-452

Safety and Tissue Residue Determination of Gatifloxacin in Broiler Chicken

Gatifloxacin is a fluoroquinolone having broad-spectrum activity and good antibacterial activity at low plasma/tissue concentration. The present study was designed to investigate safety of gatifloxacin (10 mg/kg body weight) after repeated oral administration at 12 hours interval for 14 days in broiler chickens and to determine tissue concentration of the drug following oral administration (10 mg/kg body weight) for 5 days. Repeated oral administration of gatifloxacin in broiler chickens was found safe based on evaluation of hematological (Hb, PCV and TLC), biochemical (AST, ALT, ALP, LDH, Serum uric acid, Serum Creatinine, Blood glucose and Total bilirubin) and histopathology of liver, kidney, heart and joint cartilage. Drug concentration in tissue was determined using High Performance Liquid Chromatography (HPLC). The concentration of gatifloxacin was found 0.75 ± 0.04 µg/g after fourth dose and 0.22 ± 0.07 µg/g after tenth dose respectively in liver, whereas in skeletal muscles the concentration of gatifloxacin was below the limit of quantification after fourth dose and after tenth dose gatifloxacin was not detected